Our vision in Oncology and Hematology Care

Excelling in science, transforming patients’ lives



Cutting-edge science translated into therapies for patients

We are committed to transforming patients’ lives through innovation and excellence. To deliver life-changing medicines, we are exploring various signaling pathways as part of a diversified Oncology portfolio.

We engage in cutting-edge research with a major focus on apoptosis and immuno-oncology. Our pipeline includes several molecules from the Bcl-2 family and a variety of immunotherapies such as tumor targeting anti-bodies, immunomodulators, adoptive cell therapies (CART cells) and antibody drug conjugate (ADC).

Cross-functional teams committed to deliver tailored therapeutic solutions for patients

Our cross-functional teams are committed to create value for patients by developing meaningful therapeutic solutions that will change patients’ lives.

We are guided by our commitment to build bridges to innovative anti-cancer therapies for patients.

We are driven by scientific excellence and independent innovation to shape a new generation of anti-cancer solutions.

Large partnership network allowing us to investigate a broad number of solutions for patient unmet needs

We strongly believe true innovation is found through diversity and collaboration. We partner with a broad range of oncology stakeholders, including leading academic centers, research institutes, biotechnology start-ups and large pharmaceutical companies across the globe. Our partnership network helps us build a connected scientific environment driven by one mission: to provide patients with novel therapeutic options in areas with high unmet need.

Ethics and compliance in all our activities

At Servier we are guided by high ethical standards. We are compliant with pharmaceutical industry principles, regulations and guidelines.